The Green Rush has been nothing more than an initial surge in prices followed by a multi-year decline. Delayed licensing and black-market competition proved to be very heavy obstacles for weed growers. In fact, all publicly traded cannabis companies have lost significant value save for one outlier: IIPR. As for profitability, very few can make that claim, but we look at one that can. Today, we ask which is the better buy, Aurora Cannabis (NASDAQ: ACB) or Trulieve Cannabis (OTCMKTS: TCNNF)?
As one of the leading cannabis companies in Canada, Aurora is poised to take advantage of the growing adoption of marijuana for recreational and medicinal use. And when (not if) marijuana is legalized federally in the U.S., Aurora's profits are sure to soar. In a long-term effort to cut costs, the company reported continued success on that front in its last quarterly report (Q1 2022), where it reported an 88% drop in net loss year-over-year (YoY). Additionally, net cash used for operations decreased by nearly 80% while cash and equivalents rose by over 145% in the same period.
However, the company still operates at a loss and has had to issue shares in the past to stay afloat. In fact, Aurora's outstanding shares grew over 103% from 97.41 million shares to 198.23 million shares in the last two years alone. The company's stock price is down year-to-date (YTD) and has dropped 54% YoY.
Trulieve operates primarily in Florida, where it has 113 stores and roughly 50% of the state's market. It belongs to the very limited club of profitable weed growers in the industry and has since 2017. A few months ago, the company completed the acquisition of Harvest Health to become the largest and most profitable multi-state cannabis company in the U.S.
Now for the numbers. As per its latest quarterly report (Q3 2021), revenues are up nearly 65% and gross profit climbed over 50%, YoY. Furthermore, net income surged nearly 50% as well and EBITDA rose over 46% in the same time period. Really impressive figures for any company, let alone one that deals in cannabis.
Growing competition is always a concern. However, as most cannabis companies are still struggling to reach profitability, it won't be much of a worry for Trulieve
Trulieve is the clear winner as one of the few profitable weed firms on the market. With its recent acquisition, there is little doubt that future earnings reports will continue to impress.
The Home of Successful Investing.
© 2024 MyWallSt Ltd. All rights reserved.
Services
Social
Company
Support
This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.